We’ll cover where the power to regulate/enforce gets vested, and through which agency/agencies, how cannabis becomes legalized: whether through legislation, ballot measures, or litigation, and the COVID Impact: what an “essential” designation means for cannabis as a driver of international economic development.
Medical Cannabis: Overview of Emerging Legal Issues and their Impact on the International Market. The international panel of experts will notably discuss the differences in regulations between medical cannabis and pharmaceutical cannabis, how IP is becoming an essential topic with pharmaceutical cannabis medicines, and how it could also impact medical cannabis in the short run.
Panelists will explore the current state of cannabis legalization in various regions throughout the Americas and highlight emerging markets with high growth potential. Attendees will leave this panel with a deeper understanding of the current state and future potential of emerging cannabis markets in the Americas, as well as insights and strategies for success in these exciting and rapidly evolving markets.
Attendees will gain an overview of the UK Cannabis markets, including an overview of the small but growing medical segment, as well as the booming CBD and wellness industries.
This panel seeks to address the pathways for federal cannabis reform in the 117th
Congress, considering legislative vehicles, political pragmatism, and actions of the
Administration.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
This session will look at how an international supply chain for recreational cannabis products can be designed and how the enormous demand for products from legal markets can be satisfied. What conditions need to be created at the level of international law to make global trade possible? And what about import duties, safety standards and Intellectual Property?